US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD),
Stocks to Buy or Sell. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks to buy and sell highlighted in Jim Cramer’s latest calls. Jim ...
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the ...
With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...
President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, are quickly slapped down in ...
Shares were mixed in thin Asian trading on Monday after U.S. stocks edged back from their all-time high. Oil prices fell and ...
VANCOUVER, BC / ACCESS Newswire / January 30, 2025 / Revolve Renewable Power Corp. ("Revolve" or the "Company"), a North American owner, operator and developer of renewable energy projects, ...
US stocks closed lower afer the S&P 500 touched an intraday record high early in the day. As tariff worries eased, mixed ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback